Similar articles

• Transfusion management of sickle cell disease.

  Wayne AS, Kevy SV, Nathan DG. Wayne AS, et al. Blood. 1993 Mar 1;81(5):1109-23. Blood. 1993. PMID: 8443373 Review. No abstract available.
• [Alloimmunization in poly-transfused patients with hemoglobin S disease].

  Gómez Oliva P, Basanta Otero P, González Villalonga C, Batista Veranes M, Orbeal Aldama L, García Echevarría M. Gómez Oliva P, et al. Sangre (Barc). 1985;30(4-A):406-10. Sangre (Barc). 1985. PMID: 4071354 Spanish. No abstract available.
• To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions.

  Zimring JC, Spitalnik SL. Zimring JC, et al. Transfusion. 2009 Sep;49(9):1776-8. doi: 10.1111/j.1537-2995.2009.02339.x. Transfusion. 2009. PMID: 19735500 No abstract available.
• Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.

  Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, Galactéros F, Bierling P. Noizat-Pirenne F, et al. Haematologica. 2007 Dec;92(12):e132-5. doi: 10.3324/haematol.12074. Haematologica. 2007. PMID: 18055978
• Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines.

  Josephson CD, Su LL, Hillyer KL, Hillyer CD. Josephson CD, et al. Transfus Med Rev. 2007 Apr;21(2):118-33. doi: 10.1016/j.tmrv.2006.11.003. Transfus Med Rev. 2007. PMID: 17397762 Review.